Share on LinkedInShare on LinkedIn

ARTICLE · 06 FEBRUARY 2014

Methods Of Medical Treatment: Still Not An "Invention" In Canada

On January 27, 2014, the Federal Court of Appeal in Novartis Pharmaceuticals Canada Inc. v. Cobalt Pharmaceuticals Co., 2014 FCA 17, upheld the Federal Court’s denial of an application for a prohibition order under the Canadian Patented Medicines (Notice of Compliance) Regulations on the basis that the impugned patent was directed to a method of medical treatment.

CanadaIntellectual Property

On January 27, 2014, the Federal Court of Appeal in Novartis Pharmaceuticals Canada Inc. v. Cobalt Pharmaceuticals Co., 2014 FCA 17 (Novartis), upheld the Federal Court's denial of an application for a prohibition order under the Canadian Patented Medicines (Notice of Compliance) Regulations on the basis that the impugned patent was directed to a method of medical treatment.  With this third decision1 on alleged methods of medical treatment in the past year alone, Canadian courts continue to hold methods of medical treatment to be unpatentable, while providing only limited guidance about the limits of permissible claiming. 

In Novartis, the claims at issue were directed to a particular frequency of dosing zoledronic acid to treat osteoporosis, namely intermittent administration about once a year. For example, claim 16 was directed to "use of zoledronic acid for the treatment of postmenopausal osteoporosis wherein the zoledronic acid ... is in a unit dosage form of

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from